SRZNW — Surrozen, Inc.

Surrozen (SRZNW) Q4 2022 Earnings Call Summary

1. Key Financial Results and Metrics

• Cash, cash equivalents, and marketable securities stood at approximately $76 million at the end of 2022.
• The company anticipates a cash runway extending into the second half of 2024.
• A restructuring plan is expected to reduce operating expenses by approximately 15% in 2023 compared to 2022.

2. Strategic Updates and Business Highlights

• Surrozen is focused on leveraging its proprietary Wnt pathway technology to develop tissue-selective antibodies aimed at treating severe diseases.
• Two lead clinical programs are highlighted:
  • SZN-043: Targeting severe alcoholic hepatitis, with the first patient enrolled in a Phase I trial. The company aims to progress to a Phase Ib trial in 2024.
  • SZN-1326: Targeting inflammatory bowel disease, with a voluntary pause in enrollment due to observed liver enzyme elevations. The company plans to resume dosing in healthy volunteers with a modified dosing strategy.
• A partnership with Boehringer Ingelheim was established for SZN-413, aimed at retinal diseases, with a potential milestone payment of $10 million expected upon candidate nomination by year-end 2023.
• Research programs are advancing in corneal and lacrimal gland diseases, with expectations to move at least one program into development in 2023.

3. Forward Guidance and Outlook

• For SZN-043, data from the Phase I trial in chronic liver disease patients is expected by the end of 2023, with proof-of-concept data anticipated in the second half of 2024.
• For SZN-1326, the company plans to initiate a Phase Ib trial in ulcerative colitis patients in 2024, with proof-of-concept data also expected in the second half of 2024.
• The company is prioritizing investments in advanced discovery programs while maintaining a strong balance sheet.

4. Bad News, Challenges, or Points of Concern

• Adverse events related to liver enzyme elevations were observed in both lead programs, prompting a voluntary pause in the SZN-1326 trial. This raises concerns about the safety profile of the candidates, particularly in hepatically impaired patients.
• The company acknowledges that the observed transaminase elevations could be linked to the Wnt pathway activation, which may complicate the clinical development of both SZN-043 and SZN-1326.
• There is uncertainty regarding the translation of animal model data to human subjects, particularly concerning dosing strategies and potential adverse effects.

5. Notable Q&A Insights

• The CEO clarified that the Phase I study for SZN-043 is focused on chronic liver disease patients, which may include those with fibrosis but not necessarily cirrhosis.
• Questions regarding the dosing strategy for SZN-1326 revealed that the company is adopting a MABEL (minimum anticipated biological effect level) approach to mitigate risks observed in initial cohorts.
• The half-life of SZN-1326 is approximately 5 days, with potential dosing regimens being considered for every other week or less frequent based on biological effects.
• The Q&A highlighted the need for further investigation into the liver-related adverse events and the company's ongoing efforts to understand the mechanisms behind these observations.

Overall, while Surrozen is making progress in its clinical programs and partnerships, it faces significant challenges regarding safety concerns and the need to validate its therapeutic approaches in human trials.